Cathie Wood is doubling down on her investment in Tempus AI, reinforcing her confidence in the AI-driven precision technology firm. Simultaneously, Wood offloaded nearly 42,000 shares of Rocket Lab USA, signaling a strategic portfolio shift.
Cathie Wood’s ARK Investment ETFs have continued to scoop up shares of Tempus AI (TEM). On March 12, following the announcement of Tempus AI’s acquisition of Deep 6 AI, Wood’s ARK Innovation ETF (ARKK) purchased 29,845 shares, valued at approximately $1.36 million. This buy comes as part of ARK’s routine daily trading activity.
Meanwhile, Wood’s funds sold 41,839 shares of Rocket Lab USA (RKLB), a space exploration company, from two of ARK’s ETFs—ARK Space Exploration & Innovation ETF (ARKQ) and ARK Autonomous Technology & Robotics ETF (ARKQ). The move highlights ARK’s growing focus on AI-powered precision medicine.
How the Deep 6 AI Acquisition Strengthens Tempus AI
Deep 6 AI specializes in precision research for healthcare and life sciences, offering a real-time medical data platform that streamlines patient recruitment for clinical trials. By acquiring Deep 6 AI, Tempus AI enhances its capabilities, improving the efficiency of clinical trials and further cementing its position in the AI-powered medical technology space.
Ark Invest’s recent buying spree indicates strong confidence in Tempus AI’s future growth. On March 11, Wood purchased 94,251 shares of Tempus AI, valued at $4.29 million. Over the past five trading sessions, TEM stock has dropped by 7.1%, presenting what Wood sees as a buying opportunity.
Following these acquisitions, Tempus AI now ranks eighth among the top ten holdings in ARKK, representing 4.37% of the fund’s total portfolio. Wood’s investment strategy suggests a long-term bullish outlook on AI-driven precision medicine.
Hedge Funds Display Confidence in Tempus AI
Hedge funds are also increasingly optimistic about Tempus AI’s potential. Data from the TipRanks Hedge Fund Trading Activity Tool indicates that hedge fund holdings in TEM stock increased by 3.2 million shares last quarter, resulting in a Very Positive Hedge Fund Confidence Signal.
Notably, ARK Invest ETFs were among the largest accumulators of Tempus AI stock last quarter, reporting a total holding value of $186.34 million.
Is Tempus AI Stock a Good Investment?
Market analysts remain split on Tempus AI’s stock trajectory. TipRanks analysts have assigned TEM stock a Moderate Buy rating, with five Buy ratings and five Hold ratings. The average price target stands at $63.67, suggesting a potential 39.9% upside from current levels.
Year-to-date, Tempus AI stock has surged 34.8%, making it one of the notable gainers in the AI and biotechnology sectors.
Cathie Wood’s continued investment in Tempus AI highlights her strong conviction in AI-driven healthcare solutions. As hedge funds and institutional investors increase their stakes, Tempus AI’s growth trajectory looks promising. However, with analysts divided, investors should weigh the stock’s high growth potential against market volatility before making investment decisions.
For more AI news, click here.
